Michael Pokabla, DO
Ophthalmology · Pittsburgh, PANPI 1154531291
Payments from drug & device makers
Across 185 payments — averaging $39.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$921
- Bausch & Lomb, A Division Of Bausch Health US, LLC$838
- Glaukos Corporation$813
- Tarsus Pharmaceuticals, Inc.$609
- Amgen$488
- plus $2K from 19 others
What the payments were for
- Travel & lodging$75810%
- Food & beverage$6,52588%
- Other$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $1,669 |
| Alcon | 35 | $921 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $838 |
| Glaukos Corporation | 8 | $813 |
| Tarsus Pharmaceuticals, Inc. | 30 | $609 |
| Amgen(2 entities) | 6 | $488 |
| Bausch & Lomb Americas Inc. | 21 | $395 |
| Sight Sciences, Inc. | 6 | $372 |
| Kala Pharmaceuticals, Inc. | 5 | $174 |
| Sun Pharmaceutical Industries Inc. | 7 | $152 |
| Sanofi | 1 | $122 |
| Carl Zeiss Meditec USA, Inc. | 1 | $111 |
| Ocular Therapeutix, Inc. | 5 | $101 |
| Dompe US, Inc. | 3 | $97 |
| Aerie Pharmaceuticals, Inc. | 5 | $97 |
| Spark Therapeutics, Inc. | 1 | $92 |
| Ivantis, Inc | 2 | $73 |
| Merz Pharmaceuticals, LLC | 2 | $63 |
| NEW World Medical,inc. | 2 | $55 |
| Novartis | 3 | $55 |
| Rayner Intraocular Lenses Limited | 2 | $32 |
| Thea Pharma Inc. | 1 | $23 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $16 |
| Omeros Corporation | 1 | $15 |
| Eyepoint US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$758
- XEN GLAUCOMA TREATMENT SYSTEM$471
- TEPEZZA$375
- XEN$239
- OMNI(R) SURGICAL SYSTEM (US)$132
- LUMIGAN$125
- COMBIGAN$125
- VYZULTA$125
- Rhopressa$125
- Rocklatan$125
- XDEMVY$122
- FABRAZYME$122
- INVELTYS$118
- IACCESS$116
- iStent inject W$116
- iStent infinite Trabecular Micro-Bypass System Model iS3$115
- DURYSTA$115
- OMNI$112
- LUMERA 300$111
- iDose$109
How this compares
$7,394 in reported general payments places this provider in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 560 | $294,586 |
| Brimonidine Tartrate | 831 | $57,268 |
| Travoprost | 188 | $51,859 |
| Alphagan PBrimonidine Tartrate | 103 | $49,755 |
| Prednisolone Acetate | 965 | $47,004 |
| Brinzolamide | 181 | $45,359 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 123 | $35,847 |
| CombiganBrimonidine Tartrate/Timolol | 67 | $30,550 |
| VyzultaLatanoprostene Bunod | 68 | $28,534 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 180 | $27,818 |
| RocklatanNetarsudil Mesylat/Latanoprost | 49 | $27,314 |
| RhopressaNetarsudil Mesylate | 61 | $26,283 |
| Latanoprost | 1,550 | $23,851 |
| RestasisCyclosporine | 27 | $22,949 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,125 | $22,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis | $1,669 | $397,839757 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $97 | $53,597110 claims |
| AlconSimbrinza, Azopt | $921 | $42,924140 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $395 | $28,53468 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $838 | $1,98312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Pittsburgh
- Francis MahPittsburgh$1.2M
- Robert NoeckerPittsburgh$634K
- Srinivas KondapalliPittsburgh$215K
- Deepinder DhaliwalPittsburgh$170K
- Deval ParanjpePittsburgh$121K
- Ian ConnerPittsburgh$103K
- Vishal JhanjiPittsburgh$80K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.